On the other hand, treatment with the chymase-specific inhibitor, TY-51469, significantly suppressed TGF-β1 gene expression, which was associated with decreased collagen I expression and marked attenuation of both cardiac hypertrophy and fibrosis. The gene discussed is CMA1; the disease is cardiac hypertrophy.